Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 6/20 | 0.68 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.68 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.68 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.67 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.67 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.65 |
| ▸ | GRM5 | P41594 | 5/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14085289 | 0.85 | CHRNB2 (0.69) | CYP2A6CHRNB2CHRNA4CYP2C9CYP2B6 | |
| SCHEMBL3673693 | 0.82 | CHRNB2 (0.69) | CYP2A6CHRNB2CHRNA4CYP2C9CYP2B6 | |
| SCHEMBL3613286 | 0.81 | CYP2A6 (1.00) | CYP2A6CHRNB2CHRNA4CYP2C9CYP2B6 | |
| SCHEMBL3064618 | 0.80 | CHRNB2 (0.67) | CYP2A6CHRNB2CHRNA4CYP2C9CYP2B6 | |
| SCHEMBL16123099 | 0.80 | CYP11B2 (0.57) | CYP2A6CHRNB2CHRNA4CYP2C9CYP2B6 | |
| SCHEMBL3796332 | 0.80 | CYP2A6 (0.67) | CYP2A6CHRNB2CHRNA4CYP2C9CYP2B6 | |
| SCHEMBL3603698 | 0.80 | CYP2A6 (1.00) | CYP2A6CHRNB2CHRNA4CYP2C9CYP2B6 | |
| SCHEMBL31044520 | 0.80 | CYP2A6 (0.67) | CYP2A6CHRNB2CHRNA4CYP2C9CYP2B6 | |
| SCHEMBL30938347 | 0.80 | CYP2A6 (0.67) | CYP2A6CHRNB2CHRNA4CYP2C9CYP2B6 | |
| SCHEMBL30499829 | 0.80 | CYP2A6 (1.00) | CYP2A6CHRNB2CHRNA4CYP2C9CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103827104-A | Bicarbocyclic and tricarbocyclic ethynyl derivatives and uses of same | LUNDBECK & CO AS H | 2014-05-28 | — | — | CN | claimed |
| US-11564930-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | ENODIA THERAPEUTICS SAS (FR) | 2022-05-19 | — | — | US | disclosed |
| US-20210070744-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | RIGEL PHARMACEUTICALS, INC. (US) | 2021-03-11 | — | — | US | disclosed |
| US-10683281-B2 | GLP-1 receptor agonists and uses thereof | PFIZER INC. (US) | 2020-06-16 | — | — | US | disclosed |
| CN-109790122-A | Heterocyclic compound | 武田药品工业株式会社 | 2019-05-21 | — | — | CN | disclosed |
| CN-107848964-A | EBNA1 inhibitors and methods of using the same | 威斯塔解剖学和生物学研究所 | 2018-03-27 | — | — | CN | disclosed |
| US-9802904-B2 | Inhibitors of the USP1/UAF1 deubiquitinase complex and uses thereof | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2017-10-31 | — | — | US | disclosed |
| US-9580425-B2 | Pyrido[3,4-b] indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150344443-A1 | INHIBITORS OF THE USP1/UAF1 DEUBIQUITINASE COMPLEX AND USES THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN (US) | 2015-12-03 | — | — | US | disclosed |
| WO-2014105952-A2 | INHIBITORS OF THE USP1/UAF1 DEUBIQUITINASE COMPLEX AND USES THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-07-03 | — | — | WO | disclosed |
| CN-103827104-A | Bicarbocyclic and tricarbocyclic ethynyl derivatives and uses of same | LUNDBECK & CO AS H | 2014-05-28 | — | — | CN | disclosed |
| US-20130190344-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130184304-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130184303-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130137705-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2013-05-30 | — | — | US | disclosed |
| US-20080188527-A1 | Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer | HUMAN BIOMOLECULAR RESEARCH INSTITUTE | 2008-08-07 | — | — | US | disclosed |
| CN-1984911-A | 3- (heteroaryl-oxy) -2-alkyl-1-aza-bicycloalkyl derivatives as alpha 7-NACHR ligands for the treatment of CNS disorders | NOVARTIS AG (CH) | 2007-06-20 | — | — | CN | disclosed |
| EP-1303615-A2 | FERMENTATION PROCESS FOR EPOTHILONES | Kosan Biosciences, Inc. (US) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002008440-A2 | FERMENTATION PROCESS FOR EPOTHILONES | KOSAN BIOSCIENCES, INC. (US) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184304-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | CYP2A6 969/4885CHRNB2 40/4885CHRNA4 23/4885 |
| US-20130190344-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | CYP2A6 969/4885CHRNB2 40/4885CHRNA4 23/4885 |
| US-20210070744-A1 | HETEROCYCLIC RIP1 KINASE INHIBITORS | RIPK1, RIPK2, RIPK3 | CYP2A6 4715/4885CHRNB2 4270/4885CHRNA4 4571/4885 |
| US-20080188527-A1 | Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer | CYP2A13, CYP2A6, CYP2B6 | CYP2A6 2/4885CHRNB2 22/4885CHRNA4 15/4885 |
| US-10683281-B2 | GLP-1 receptor agonists and uses thereof | GLP1R, GIPR, GCGR | CYP2A6 1543/4885CHRNB2 1437/4885CHRNA4 882/4885 |
| US-20150344443-A1 | INHIBITORS OF THE USP1/UAF1 DEUBIQUITINASE COMPLEX AND USES THEREOF | USP1, UHRF1, UBQLN1 | CYP2A6 2859/4885CHRNB2 4375/4885CHRNA4 4629/4885 |
| US-20220153732-A1 | PROTEIN SECRETION INHIBITORS | SEC61B, SEC61A1, SEC61G | CYP2A6 2681/4885CHRNB2 4568/4885CHRNA4 4847/4885 |
| US-20130184303-A1 | PYRIDO[4,3-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | CYP2A6 969/4885CHRNB2 40/4885CHRNA4 23/4885 |
| US-20130137705-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | CYP2A6 949/4885CHRNB2 40/4885CHRNA4 23/4885 |
| US-11564930-B2 | RIP1 inhibitory compounds and methods for making and using the same | RIPK1, RIPK2, RIPK3 | CYP2A6 4848/4885CHRNB2 3723/4885CHRNA4 4478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.